Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company Drug

Yifan Pharmaceutical’s Subsidiary Receives FDA Approval for Ryzneuta (F-627)

Fineline Cube Nov 20, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd.,...

Company Drug

AstraZeneca Receives FDA Approval for Truqap in HR-Positive, HER2-Negative Breast Cancer

Fineline Cube Nov 20, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received regulatory...

Company Drug

Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors

Fineline Cube Nov 17, 2023

Alphamab Oncology (HKG: 9966) has released preliminary data from a Phase I clinical study on...

Policy / Regulatory

Final Results of China’s Round 9 Volume-Based Procurement Tender Announced

Fineline Cube Nov 17, 2023

The National Allied Procurement Office has released the finalized results and tender bid allocations for...

Company Drug

BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC

Fineline Cube Nov 17, 2023

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY)...

Drug Policy / Regulatory

CDE Releases 76th Batch of Chemical Generic Reference Preparations

Fineline Cube Nov 17, 2023

The Center for Drug Evaluation (CDE) has released the 76th batch of chemical generic reference...

Company Drug

Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study

Fineline Cube Nov 17, 2023

China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II...

Company Drug

Easton Pharmaceutical Receives FDA Approval for Generic Nalmefene

Fineline Cube Nov 17, 2023

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced receiving Abbreviated New Drug Application (ANDA)...

Deals R&D

University of Hong Kong to Host Infectious Disease Labs by UN’s Vaccine Institute and Cambridge University

Fineline Cube Nov 17, 2023

The University of Hong Kong (HKU) is poised to host new infectious disease laboratories established...

Company

BeiGene Ltd Opens Global Industrialization Base for Small-Molecule Drugs in Suzhou

Fineline Cube Nov 17, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the inauguration of its small-molecule...

Company Drug

Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia

Fineline Cube Nov 17, 2023

Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare...

Company Deals

Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services

Fineline Cube Nov 17, 2023

Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an...

Company Drug

Vertex Pharmaceuticals and CRISPR Therapeutics Receive Conditional Approval for CRISPR Gene-Editing Therapy

Fineline Cube Nov 17, 2023

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) have received conditional approval from the...

Company Deals

Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen

Fineline Cube Nov 17, 2023

Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...

Company Deals

Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry

Fineline Cube Nov 16, 2023

Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum...

Company Drug

SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA

Fineline Cube Nov 16, 2023

SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National...

Company

Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Nov 16, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published...

Company Medical Device

Sino Medical Sciences Technology’s HT Supreme Stent Gains Brazilian Market Approval

Fineline Cube Nov 16, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108) a leading China-based medical device company, has announced...

Company Deals

Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies

Fineline Cube Nov 16, 2023

Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...

Company Deals

AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management

Fineline Cube Nov 16, 2023

US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group...

Posts pagination

1 … 393 394 395 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.